KR102791419B1 - 세포 함유 의약 조성물 - Google Patents
세포 함유 의약 조성물 Download PDFInfo
- Publication number
- KR102791419B1 KR102791419B1 KR1020217037758A KR20217037758A KR102791419B1 KR 102791419 B1 KR102791419 B1 KR 102791419B1 KR 1020217037758 A KR1020217037758 A KR 1020217037758A KR 20217037758 A KR20217037758 A KR 20217037758A KR 102791419 B1 KR102791419 B1 KR 102791419B1
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- macrophages
- cell population
- cell
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/17—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2019/032322 WO2021033247A1 (ja) | 2019-08-19 | 2019-08-19 | 細胞含有医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220003564A KR20220003564A (ko) | 2022-01-10 |
| KR102791419B1 true KR102791419B1 (ko) | 2025-04-08 |
Family
ID=74659865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217037758A Active KR102791419B1 (ko) | 2019-08-19 | 2019-08-19 | 세포 함유 의약 조성물 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US12460182B2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7500083B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102791419B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021033247A1 (cg-RX-API-DMAC7.html) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6372782B2 (ja) * | 2012-09-28 | 2018-08-15 | 公益財団法人神戸医療産業都市推進機構 | 虚血性疾患治療に適した細胞を含む細胞群の生体外増幅方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014027474A1 (ja) | 2012-08-17 | 2014-02-20 | 株式会社Clio | 心筋梗塞の修復再生を誘導する多能性幹細胞 |
| AU2015297347B2 (en) | 2014-08-01 | 2021-05-27 | PuREC Co., Ltd | Method for evaluating quality of human mesenchymal stem cell, and monoclonal antibody for use in said method |
| US20160287638A1 (en) | 2015-04-02 | 2016-10-06 | Stemedica Cell Technologies, Inc. | Ischemic tolerant cells and cellular factors in the treatment of peripheral artery disease |
| EP3297615A1 (en) * | 2015-05-20 | 2018-03-28 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for modulation polarization and activation of macrophages |
| EP3299453B1 (en) * | 2016-09-23 | 2019-05-08 | Xcell Medical Solutions, S.L. | Cell therapy with polarized macrophages for tissue regeneration |
-
2019
- 2019-08-19 US US17/612,441 patent/US12460182B2/en active Active
- 2019-08-19 WO PCT/JP2019/032322 patent/WO2021033247A1/ja not_active Ceased
- 2019-08-19 JP JP2021541368A patent/JP7500083B2/ja active Active
- 2019-08-19 KR KR1020217037758A patent/KR102791419B1/ko active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6372782B2 (ja) * | 2012-09-28 | 2018-08-15 | 公益財団法人神戸医療産業都市推進機構 | 虚血性疾患治療に適した細胞を含む細胞群の生体外増幅方法 |
Non-Patent Citations (2)
| Title |
|---|
| MASUDA H. et al., J. Am. Heart Assoc., 2014, vol. 3, e000743 |
| Zhao Cheng et al., Bone marrow-derived innate macrophages attenuate oxazolone-induced colitis, Cellular Immunology 311 (2017) 46-53* |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7500083B2 (ja) | 2024-06-17 |
| KR20220003564A (ko) | 2022-01-10 |
| WO2021033247A1 (ja) | 2021-02-25 |
| JPWO2021033247A1 (cg-RX-API-DMAC7.html) | 2021-02-25 |
| US20220218744A1 (en) | 2022-07-14 |
| US12460182B2 (en) | 2025-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dazzi et al. | The role of mesenchymal stem cells in haemopoiesis | |
| US10722541B2 (en) | Methods for treating radiation or chemical injury | |
| Tuder et al. | Relevant issues in the pathology and pathobiology of pulmonary hypertension | |
| US20140017209A1 (en) | Methods for treating radiation or chemical injury | |
| TW201130977A (en) | Mesenchymal stem cells (MSCs) isolated from mobilized peripheral blood | |
| BRPI0709349A2 (pt) | métodos para expansão celular e usos de células e de meios condicionados produzidos através deles para terapia | |
| KR20160131112A (ko) | 간엽줄기세포 활성화제, 활성화된 간엽줄기세포 및 그 제조 방법 | |
| Swart et al. | Mesenchymal stromal cells for treatment of arthritis | |
| CN113853206A (zh) | 脑梗塞的功能恢复 | |
| US6821513B1 (en) | Method for enhancing hematopoiesis | |
| Milazzo et al. | Therapeutic efficacy of intracerebral hematopoietic stem cell gene therapy in an Alzheimer’s disease mouse model | |
| US12178849B2 (en) | Autoimmune disease treatment with chemokine-loaded alginate microparticles | |
| AU2013235600B2 (en) | Isolation and use of human lymphoid organ-derived suppressive stromal cells | |
| JPWO2020158924A1 (ja) | 母児間免疫寛容を誘導する方法 | |
| CN114901806A (zh) | 细胞群以及其取得方法 | |
| US20200291109A1 (en) | Composition to induce bone marrow stem cell mobilization | |
| WO2022195117A1 (en) | Mesenchymal stem cells for use in increasing ex-vivo organ life | |
| van Os et al. | Engraftment of syngeneic bone marrow is not more efficient after intrafemoral transplantation than after traditional intravenous administration | |
| WO2014193895A1 (en) | Ex vivo perfusion of donor organs prior to transplantation using mesenchymal stem cells | |
| Norol et al. | GFP-transduced CD34+ and Lin− CD34− hematopoietic stem cells did not adopt a cardiac phenotype in a nonhuman primate model of myocardial infarct | |
| JP7500083B2 (ja) | 細胞含有医薬組成物 | |
| Bonaros et al. | CCR3-and CXCR4-mediated interactions regulate migration of CD34+ human bone marrow progenitors to ischemic myocardium and subsequent tissue repair | |
| US20130287747A1 (en) | Methods of Treating Acute Kidney Injury Using Mesenchymal Stem Cells | |
| WO2009046058A1 (en) | A method to amplify cardiac stem cells in vitro and in vivo | |
| US20050232905A1 (en) | Use of peripheral blood cells for cardiac regeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PX0901 | Re-examination |
St.27 status event code: A-2-3-E10-E12-rex-PX0901 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| PX0701 | Decision of registration after re-examination |
St.27 status event code: A-3-4-F10-F13-rex-PX0701 |
|
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |